TORONTO–(BUSINESS WIRE)–TOTAL30® for Astigmatism and DAILIES TOTAL1® for Astigmatism launches in Canada.
Author: Business Wire
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent, product-specific J-code for IHEEZO™ (…
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an …
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
VAUGHAN, Ontario & TAMPERE, Finland–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Modulight Corporation (“Modulight”), a bi…
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourt…
Radiance Therapeutics to Present at Glaucoma 360 New Horizons Forum
SAN FRANCISCO–(BUSINESS WIRE)–Radiance Therapeutics, Inc. (RadianceTx®), an innovation leader in ophthalmic devices, today announced that Dr. Laurence Marsteller, Chief Executive Officer, will present the company at the Glaucoma Research Foundation h…
Global Optometry Market to Reach $78.9 Billion by 2027 at a 3.8% CAGR – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optometry: Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global Optometry Market to Reach $78.9 Billion by 2027 In the changed post COVID-19 business landscape, the global ma…
NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
EMERYVILLE, Calif.–(BUSINESS WIRE)—- $NBY #Avenova–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Justin Hall, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 2:30 …
Global Intraocular Lenses Market 2022 to 2027: Soaring Screen Time and Increasing Incidence of Computer Vision Syndrome Drives Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Intraocular Lenses: Global Market Outlook” report has been added to ResearchAndMarkets.com’s offering. In this report, the market has been segmented based on organization size, component, provider, type, industry and geogr…
Dr. Rohit Varma Shares Eye-Disease Research at the 2nd Mexico-United States Symposium on Vision Health
MEXICO CITY–(BUSINESS WIRE)–More than 40 leading ophthalmologists, vision researchers, and public health/policy experts are sharing data and holding discussions on the global burden of diabetes-related eye disease to develop a plan to address this le…
AER Launches The New RE:view–A Journal of Practice
ALEXANDRIA, Va.–(BUSINESS WIRE)–The Association for Education and Rehabilitation of the Blind and Visually Impaired (AER), is excited to announce that the first issue of its new practitioner-focused journal—The New RE:view—will be published on Januar…
Oxular Limited anuncia la autorización IND de OXU-001 supracoroidal para el tratamiento del edema macular diabético
OXFORD, Reino Unido–(BUSINESS WIRE)–Oxular Limited, una empresa de dispositivos oftálmicos en fase clínica que desarrolla terapias dirigidas a largo plazo para trastornos de la retina con el fin de mejorar la visión de los pacientes, ha anunciado hoy…
HORUS PHARMA ANUNCIA UNA ALIANZA CON PLASTIC BANK POR LA QUE RECICLARÁ CERCA DE 100 TONELADAS DE MATERIALES PLÁSTICOS
BARCELONA, España–(BUSINESS WIRE)–Horus Pharma, el laboratorio independiente con sede en Francia especializado en oftalmología, reconocido por su excelencia en el desarrollo de productos «sin conservantes» para el cuidado del ojo y la pupila, anuncia…
Oxular Limited kondigt acceptatie aan van IND voor suprachoroïdale OXU-001 voor de behandeling van diabetisch macula-oedeem
OXFORD, Verenigd Koninkrijk–(BUSINESS WIRE)–Oxular Limited, een oogheelkundig bedrijf in de klinische fase dat langdurige, gerichte behandelingen voor netvliesaandoeningen ontwikkelt om het gezichtsvermogen van patiënten te verbeteren, heeft vandaag …
Oxular Limited annuncia l'accettazione dell'IND per OXU-001 sopracoroideale nel trattamento dell'edema maculare diabetico
OXFORD, Regno Unito–(BUSINESS WIRE)–Oxular Limited, azienda terapeutica oftalmica di fase clinica che sviluppa trattamenti mirati di lunga durata contro i disturbi della retina per migliorare la vista dei pazienti, oggi ha annunciato che la U.S. Food…
Oxular Limited gibt die Genehmigung der IND (Investigational New Drug, neues Prüfpräparat) für den suprachoroidalen Wirkstoff OXU-001 zur Behandlung des diabetischen Makulaödems bekannt
OXFORD, Vereinigtes Königreich–(BUSINESS WIRE)–Oxular Limited, ein in der klinischen Phase tätiges Unternehmen im Bereich der Augenheilkunde, das lang anhaltende, zielgerichtete Behandlungen für Netzhauterkrankungen entwickelt, um das Sehvermögen der…
Optometry Equipment Market Report 2022: Increasing Incidence of Digital Eye Strain Boosts Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optometry Equipment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030” report has been added to ResearchAndMarkets.com’s offer…
Oxular Limited annonce l'autorisation DNR pour l'OXU-001 suprachoroïdien dans le traitement de l'œdème maculaire diabétique
OXFORD, Royaume-Uni–(BUSINESS WIRE)–Oxular Limited, une société de matériel ophtalmologique au stade clinique qui développe des traitements ciblés de longue durée pour les troubles rétiniens afin d’améliorer la vision des patients, a annoncé aujourd’…
Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema
OXFORD, United Kingdom–(BUSINESS WIRE)–Oxular Limited, a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announced that the U.S. Food and Drug Administration has a…
Fabrinet to Announce Second Quarter 2023 Financial Results on February 6, 2023
BANGKOK–(BUSINESS WIRE)–Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced it …